Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

ARA-290 vs Klow

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

ARA-290 has stronger documented evidence (Phase 2) than Klow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

ARA-290

Phase 2

Klow

Anecdotal

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

ARA-290 Klow
Class EPO-derived peptide; innate repair receptor (IRR) agonist Four-component regenerative blend (Glow + KPV anti-inflammatory)
Drug class Tissue Repair Tissue Repair
Mechanism Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm.
Route SC injection SC injection
Half-life ~2 hrs Composite: hours to days per component (TB-500 longest)
Dosage (research) 2-4 mg SC daily for 28 days (trial protocol) Typical SC protocols deliver ~250 mcg of each component daily (per-component basis from a combined-mg vial) for 4-8 week loading cycles. Confirm vial composition with vendor before computing per-component dose
Evidence tier Phase 2 Anecdotal
Research depth 68 indexed (PubMed 51 · CT 4 · EPMC 13) —
Availability Investigational Compounding Restricted
Reported risks Injection site reactions; Phase 2/3 data limited No human-trial data on the combined formulation; each component carries its own risk profile (TB-500 WADA-banned, theoretical pro-proliferative concerns; copper accumulation at chronic GHK-Cu doses); injection-site reactions; meaningful batch-to-batch composition variability across compounders

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick ARA-290 or Klow?

ARA-290 has stronger documented evidence (Phase 2) than Klow (Anecdotal) while both occupy the tissue-repair class. When clinical-evidence tier is the deciding factor, ARA-290 is the safer pick. Klow may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between ARA-290 and Klow?

ARA-290 is classed as EPO-derived peptide; innate repair receptor (IRR) agonist; Klow is classed as Four-component regenerative blend (Glow + KPV anti-inflammatory). Reported mechanism: ARA-290, Activates IRR heterocomplex (EpoR/βcR); tissue protection without hematopoietic effect; Klow, Composite formulation layering matrikine signalling, cytoprotection, actin regulation, and NF-kB suppression: GHK-Cu (copper-peptide matrikine activating ~4,000 wound-healing / collagen-elastin genes), BPC-157 (angiogenesis via VEGFR2 + epithelial / tendon repair), TB-500 (actin sequestration + stem-cell mobilisation + anti-fibrotic), KPV (alpha-MSH-derived tripeptide inhibiting NF-kB at mucosal epithelium). Klow is essentially the Glow blend plus KPV for an inflammation-suppression arm. Reported half-life: ARA-290, ~2 hrs; Klow, Composite: hours to days per component (TB-500 longest). Routes in published studies: ARA-290, SC injection; Klow, SC injection.

Which has stronger evidence, ARA-290 or Klow?

ARA-290 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. ARA-290 is graded Phase 2, with 3 cited sources on its reference page and 68 indexed studies. Klow is graded Anecdotal, with 4 cited sources on its reference page.

Which is more accessible, ARA-290 or Klow?

Neither ARA-290 nor Klow is an FDA-approved drug. Catalog status: ARA-290, Investigational; Klow, Compounding Restricted.

Are ARA-290 and Klow ever combined?

ARA-290 and Klow appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…